Research focus is on the development of innovative technologies to treat cancer with immune cells, and their translation into first-in human clinical trials.

Research interest is in precision oncology in colorectal, pancreas and liver cancers. I develop and conduct clinical trials with novel therapeutics and work with collaborators within and outside Singapore on translational and biomarker research in these areas. In addition, I am interested in healthcare delivery and personalizing care for our cancer survivors.

Neuroblastoma is the leading cause of cancer death in children. Our research is to develop improved approaches for treating neuroblastoma through drug repurposing and predicting outcome in paediatric tumours through blood sample monitoring.

Research focus is on identifying how the harmful changes that occur in RNA molecules trigger a cell to develop into cancer which can eventually lead to the unsatisfactory treatment outcomes for patients with cancers. The long-term goal of Dr Chen’s team is to develop novel cancer therapies targeting these cancer-associated RNA changes.

Research focus is on uncovering and characterising novel signalling nodes of oncogenic RAS-driven human cancers to facilitate the development of tractable therapeutic modalities.

Research delves into deciphering the intricate immune landscape and crosstalk within the tumor microenvironment of hepatocellular carcinoma (HCC), with a keen focus on uncovering biomarkers and therapeutic avenues.

Research focuses on developing novel immunotherapies that harness the immune system to target tumors, with a particular emphasis on neoantigens. These neoantigens, which arise from tumor-specific mutations, represent a distinct class of antigens recognized by T cells, making them promising targets for precision cancer therapies. By identifying and characterizing these neoantigens, the aim is to develop personalized cancer vaccines and T cell-based therapies that improve the immune system’s capacity to recognize and eliminate tumors.

Research focus is on blood cancers to understand how the disease develops and find better ways to treat them.

Research interests are to unravel drug resistance mechanisms involving the BCL-2 family proteins, kinase and phosphatase, and redox and mitochondrial metabolism as well as to identify actionable targets using functional precision medicine techniques in hematologic and lung malignancies.